OMEROS CORP Assets, Fair Value Adjustment
OMEROS CORP (OMER) reported Assets, Fair Value Adjustment of -$5.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:AssetsFairValueAdjustment · last filed 2026-08-12
- OMEROS CORP assets, fair value adjustment for the quarter ending 2025-12-31 was -$3.73M.
- OMEROS CORP assets, fair value adjustment for the quarter ending 2025-09-30 was $13.40M.
- OMEROS CORP assets, fair value adjustment for the quarter ending 2025-06-30 was $3.15M.
- OMEROS CORP assets, fair value adjustment for the quarter ending 2025-03-31 was -$166.00K.
- OMEROS CORP assets, fair value adjustment for fiscal 2025 was $12.66M.
- OMEROS CORP assets, fair value adjustment for fiscal 2024 was -$7.97M.
- OMEROS CORP assets, fair value adjustment for fiscal 2023 was -$41.17M.
- OMEROS CORP assets, fair value adjustment for fiscal 2022 was -$14.46M.
| Period end | Assets, Fair Value Adjustment 3 month | Assets, Fair Value Adjustment 3 month as first filed | Assets, Fair Value Adjustment 6 month | Assets, Fair Value Adjustment 6 month as first filed | Assets, Fair Value Adjustment 9 month | Assets, Fair Value Adjustment 9 month as first filed | Assets, Fair Value Adjustment 12 month | Assets, Fair Value Adjustment 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$5.19M 10-Q · filed 2026-08-12 | |||||||
| 2025-12-31 | -$3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $9.68M derived: sum of 2 quarters · filed 2026-03-31 | $12.82M derived: sum of 3 quarters · filed 2026-08-12 | $12.66M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $13.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $16.55M derived: sum of 2 quarters · filed 2026-08-12 | $16.38M 10-Q · filed 2025-11-13 | $15.80M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $3.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $2.98M 10-Q · filed 2026-08-12 | $2.40M derived: sum of 3 quarters · filed 2026-08-12 | $1.67M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | -$166.00K 10-Q · filed 2025-05-15 | -$751.00K derived: sum of 2 quarters · filed 2026-03-31 | -$1.48M derived: sum of 3 quarters · filed 2026-03-31 | -$5.80M derived: sum of 4 quarters · filed 2026-03-31 | ||||
| 2024-12-31 | -$585.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$1.32M derived: sum of 2 quarters · filed 2026-03-31 | -$5.63M derived: sum of 3 quarters · filed 2026-03-31 | -$7.97M 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | -$731.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$5.04M derived: sum of 2 quarters · filed 2025-11-13 | -$7.38M 10-Q · filed 2025-11-13 | -$12.82M 10-Q · filed 2024-11-13 | -$37.07M derived: sum of 4 quarters · filed 2026-03-31 | |||
| 2024-06-30 | -$4.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$6.65M 10-Q · filed 2025-08-14 | -$8.61M 10-Q · filed 2024-08-07 | -$36.34M derived: sum of 3 quarters · filed 2026-03-31 | -$40.07M derived: sum of 4 quarters · filed 2026-03-31 | |||
| 2024-03-31 | -$2.34M 10-Q · filed 2025-05-15 | -$4.34M 10-Q · filed 2024-05-15 | -$32.02M derived: sum of 2 quarters · filed 2026-03-31 | -$35.75M derived: sum of 3 quarters · filed 2026-03-31 | -$39.58M derived: sum of 4 quarters · filed 2026-03-31 | |||
| 2023-12-31 | -$29.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$33.41M derived: sum of 2 quarters · filed 2026-03-31 | -$37.24M derived: sum of 3 quarters · filed 2026-03-31 | -$41.17M 10-K · filed 2026-03-31 | -$15.31M 10-K · filed 2024-04-01 | |||
| 2023-09-30 | -$3.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$7.56M derived: sum of 2 quarters · filed 2024-11-13 | -$11.48M 10-Q · filed 2024-11-13 | -$14.92M 10-Q · filed 2023-11-09 | $14.69M derived: sum of 4 quarters · filed 2025-03-31 | |||
| 2023-06-30 | -$3.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$7.75M 10-Q · filed 2024-08-07 | $18.42M derived: sum of 3 quarters · filed 2025-03-31 | |||||
| 2023-03-31 | -$3.92M 10-Q · filed 2024-05-15 | $22.25M derived: sum of 2 quarters · filed 2025-03-31 | ||||||
| 2022-12-31 | $26.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$14.46M 10-K · filed 2025-03-31 | -$18.63M 10-K · filed 2024-04-01 | |||||
| 2022-09-30 | -$40.63M 10-Q · filed 2023-11-09 | |||||||
| 2021-12-31 | $0.00 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |